ASX has a few biotechs involved with wound healing - Avita (AVH) and Factor Therapeutics (FTT) which have not set the world on fire due to regulatory hurdles. This could be a problem for Qbiotics as it seems like they are early stage?
Plus the recent share trades seem to be at $0.40. No idea on how many shares are on issue so hard to say whether it is cheap based on market capitalisation?
